World Cancer Day, 4 February 2024

Join us in commemorating World Cancer Day on 4th February by exploring our specially curated collection of articles that delve into the multi-faceted aspects of this pervasive disease. This collection will provide you with a comprehensive overview of the latest advancements in cancer research and treatment.

Annals of Oncology

• Diversity in clinical trials in Europe and the USA: a review of a pharmaceutical company’s data collection, reporting, and interpretation of race and ethnicity - Annals of Oncology opens in new tab/window

• ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe☆ - Annals of Oncology opens in new tab/window

• European cancer mortality predictions for the year 2024 with focus on colorectal cancer opens in new tab/window

Cancer Letters

• Drug conjugate-based anticancer therapy - Current status and perspectives opens in new tab/window

• Cope with copper: From copper linked mechanisms to copper-based clinical cancer therapies opens in new tab/window

Current Problems in Cancer

• Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors opens in new tab/window

• Innovations and Opportunities for the Integration of Palliative Care in Cancer Care opens in new tab/window

Current Problems in Cancer: Case Reports

• Mixed response to chemotherapy in triple-negative breast cancer: a case report opens in new tab/window

• A unique case of protein-losing enteropathy in the setting of immune checkpoint inhibition case report opens in new tab/window

ESMO Gastrointestinal Oncology

• ARCAD-Asia initiative: leveraging yesterday’s data for tomorrow - ESMO Gastrointestinal Oncology opens in new tab/window

• Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study - ESMO Open opens in new tab/window

ESMO Real World Data and Digital Oncology

• Equitable access to oncology clinical trials: harnessing technology to reduce geographic disparities - ESMO Real World Data and Digital Oncology (esmorwd.org) opens in new tab/window

European Journal of Cancer

• First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations opens in new tab/window

• Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network opens in new tab/window

Immuno-Oncology and Technology

• ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing - Immuno-Oncology and Technology (esmoiotech.org) opens in new tab/window

Journal of Thoracic Oncology

• LUNG CANCER WORLDWIDE COLLECTION opens in new tab/window

• The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors opens in new tab/window

• The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors opens in new tab/window

• The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic Epithelial Tumors for the Forthcoming Ninth Edition of the TNM Classification of Malignant Tumors opens in new tab/window

• The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors opens in new tab/window

• The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors opens in new tab/window

• IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer opens in new tab/window

• The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer opens in new tab/window

• The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer opens in new tab/window

• International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy opens in new tab/window

• Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial opens in new tab/window

• Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations opens in new tab/window

• Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer opens in new tab/window

• Lung Cancer Screening in Asia: An Expert Consensus Report opens in new tab/window

• Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer opens in new tab/window

• Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC opens in new tab/window

• Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial opens in new tab/window

• Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer opens in new tab/window

• Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation opens in new tab/window

• A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC opens in new tab/window

• Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study opens in new tab/window

• Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in Asian Female Never-Smokers Is as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers: A Systematic Review and Meta-Analysis opens in new tab/window

• Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib opens in new tab/window

• Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium opens in new tab/window

• Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC opens in new tab/window

• Robotic Esophagectomy Compared With Open Esophagectomy Reduces Sarcopenia within the First Postoperative Year: A Propensity Score-Matched Analysis opens in new tab/window

• Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study opens in new tab/window

• UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN) opens in new tab/window

JTO Clinical and Research Reports

• Health Care Utilization and Costs in Lung Cancer Screening Participants—A Propensity-Matched Economic Analysis opens in new tab/window

• Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience opens in new tab/window

• Comparison of Lung Cancer Surgery Outcomes in Queensland for Indigenous and Nonindigenous Australians opens in new tab/window

• Subtype of SCLC Is an Intrinsic and Persistent Feature Through Systemic Treatment opens in new tab/window

• Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy opens in new tab/window

• Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC opens in new tab/window

• Racial, Ethnic, and Socioeconomic Characteristics Independently Predict for Cachexia Risk and Associated Survival Outcomes in Stage IV NSCLC: A Brief Report opens in new tab/window

Neoplasia

• The children's brain tumor network (CBTN) – Accelerating research in pediatric central nervous system tumors through collaboration and open science opens in new tab/window

• Maestros of malignancy: Microbes as the conductors of carcinogenesis opens in new tab/window